Vida Ventures is a next-generation life sciences venture capital firm focused on building and funding transformative biomedical innovations — investing significant capital in companies developing novel therapeutics, drug discovery platforms, and related life sciences technologies. It partners deeply with founders and scientific teams over the long term, helping advance discoveries from early clinical stages toward commercialization. 

Specific Funding Stage
Seed & Early Institutional: While Vida supports companies across the growth continuum, it often participates in Seed and Series A rounds, especially for scientific enterprises emerging from translational research and early proof-of-concept.
Series A / B / C: Much of its capital deployment occurs at later early institutional stages — Series A, Series B, and Series C — reflecting its emphasis on companies advancing toward clinical development and commercialization.
Extended Support: Vida’s flexible model allows it to build and back companies regardless of stage, meaning it may also engage opportunistically in later growth financings. 

Investment Amount and Percentage Equity (Company-Level)
Typical Investment Size: Vida Ventures is known to write substantial checks in the life sciences sector, with typical round sizes often ranging from roughly $10 million to $50 million when it leads or participates in major investments.
Equity Taken:
• No fixed equity percentage is publicly advertised as a standard “deal term.” Like most institutional VC firms, Vida negotiates ownership stakes on a deal-by-deal basis with founders and co-investors based on valuation and round dynamics — typical for large, late seed to growth stage rounds.
• Industry context: In life sciences venture financings, institutional investors often secure meaningful minority positions that align with the capital and strategic value they bring (commonly in the mid-single to low-double-digit percentage range), but the specific equity percentage varies per company and negotiation rather than being a preset policy. This reflects standard venture practice for later-stage starts.

Equity Structure: Investments are generally made through priced equity or structured preferred shares consistent with later-stage venture financings, negotiated for each portfolio company.

Application / Submission Method
Submission Method: Vida primarily sources deals through industry networks, scientific founders, and strategic introductions rather than an open online application portal. Warm intros from founders, co-investors, or ecosystem partners are typically most effective for engagement.
Contact: Founders can reach Vida Ventures via [email protected] for general inquiries; limited partner and fellowship inquiries have distinct email contacts. 

Sector Focus: Life sciences, biotechnology, therapeutics, drug discovery, and related biomedical technologies.
Geography: Primarily U.S.-based investments (with offices in Los Angeles, Boston, New York, and Fort Worth), though global investment isn’t excluded if aligned with thesis.
Stage: Seed to growth-oriented institutional rounds where scientific innovation and clinical development are central. 
Team: Founders and scientific leaders with deep domain expertise and translational research potential.

Initial Screening: Review of scientific thesis, market potential, and team.

Partner Evaluation: Internal partner review to assess fit with Vida’s life sciences focus.

Due Diligence: Deep technical, clinical, and market diligence tailored to the biotech/therapeutics domain.

Term Negotiation: Negotiation of valuation, equity, governance rights, and other economic terms.

Close & Support: Legal documentation and deployment of capital with ongoing company building support.

Strategic Capital: Substantial funding for life sciences ventures — often $10M–$50M range per round depending on stage and need.
Scientific & Operational Support: Deep domain guidance from investors with strong biomedical and operational backgrounds.
Network & Industry Access: Connectivity to pharma partners, research institutions, and other strategic collaborators. Demonstrated portfolio exits (e.g., acquisitions by global pharma companies) underscore its ability to support companies through major strategic outcomes.